Cadila Healthcare has conducted Phase-III trial of ZyCoV-D (recombinant DNA) in the age group 12 years and above. The vaccine is approved for restricted use in emergencies in the age group 12 years and above.
Yesterday, Union Health Secretary Rajesh Bhushan had said that Zydus Cadila's COVID-19 vaccine ZyCoV-D will initially be used in seven states (Maharashtra, Tamil Nadu, Uttar Pradesh, Punjab, Jharkhand, Bihar, and West Bengal).
Zydus Cadila on November 8 said it had received an order to supply one crore doses of ZyCoV-D to the Indian government at ₹265 per dose. "Zydus Cadila has received an order to supply one crore doses of ZyCoV-D, the world's first Plasmid DNA Vaccine, to the Government of India at ₹265 per dose and the